Category Archives: Aulis Capital

Healthcare systems across the world are strained by rising chronic disease burdens, aging populations, and increasing costs. These pressures are accelerating a major global shift — from treatment-centered models to preventive care strategies that emphasize early detection, lifestyle interventions, and personalized monitoring. This shift is creating one of the most compelling investment frontiers in modern

The early stages of healthcare innovation are often the most critical — and the most fragile. While capital enables progress, it is rarely the determining factor in whether a breakthrough succeeds or stalls. What early-stage companies need even more is the right combination of scientific validation, clinical access, regulatory insight, and long-term strategic alignment. Scientific

Artificial intelligence has become one of the most widely discussed forces in healthcare, yet the gap between promise and real-world impact remains significant. While some AI solutions deliver measurable improvements, others fail to move beyond prototype stage or lack the clinical rigor required for adoption. Aulis Capital evaluates AI opportunities through a disciplined, science-led framework

Healthcare innovation is entering a new era defined by rapid scientific advancement, digital transformation, and shifting global demographics. Yet many of the most promising breakthroughs happen at the intersection of regions, institutions, and expertise. This is where cross-border collaboration becomes essential. At Aulis Capital, we’ve seen firsthand that the most impactful medical technologies rarely originate